Advertisement

Advertisement

MGTX Stock Latest News

MeiraGTx price target raised to $24 from $16 at RBC Capital

The FlyMeiraGTx price target raised to $24 from $16 at RBC Capital

MeiraGTx Announces Public Equity Offering to Fund Growth

PremiumCompany Announcements

MeiraGTx Announces Public Equity Offering to Fund Growth

1d ago

MeiraGTx announces three-year data from Phase 1 AQUAx study

PremiumThe Fly

MeiraGTx announces three-year data from Phase 1 AQUAx study

2d ago

MeiraGTx announces acquisition of bota-vec for treatment of XLRP

PremiumThe Fly

MeiraGTx announces acquisition of bota-vec for treatment of XLRP

2d ago

MeiraGTx Reacquires Bota-Vec Rights, Advances XLRP Program

PremiumCompany Announcements

MeiraGTx Reacquires Bota-Vec Rights, Advances XLRP Program

2d ago

MeiraGTx Reports Durable Phase 1 AQUAx Gene Therapy Data

PremiumCompany AnnouncementsMeiraGTx Reports Durable Phase 1 AQUAx Gene Therapy Data

2d ago

Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says

The Fly

Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says

4d ago

MeiraGTx price target lowered to $18 from $20 at Evercore ISI

The Fly

MeiraGTx price target lowered to $18 from $20 at Evercore ISI

17d ago

MeiraGTx’s AI Push Raises Operational, Regulatory and Data Privacy Risk Concerns

PremiumCompany Announcements

MeiraGTx’s AI Push Raises Operational, Regulatory and Data Privacy Risk Concerns

18d ago

MeiraGTx price target lowered to $26 from $30 at Piper Sandler

PremiumThe Fly

MeiraGTx price target lowered to $26 from $30 at Piper Sandler

22d ago

MeiraGTx price target raised to $16 from $14 at BofA

PremiumThe Fly

MeiraGTx price target raised to $16 from $14 at BofA

22d ago

MeiraGTx Highlights Breakthrough Gene Therapy and Strategic Alliances

PremiumCompany Announcements

MeiraGTx Highlights Breakthrough Gene Therapy and Strategic Alliances

23d ago

MeiraGTx announces FDA breakthrough therapy designation for AAV2-hAQP1

PremiumThe FlyMeiraGTx announces FDA breakthrough therapy designation for AAV2-hAQP1

23d ago

MGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

MGTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

1M ago

Controversial Prasad leaving FDA, NYT reports

The Fly

Controversial Prasad leaving FDA, NYT reports

1M ago

MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy

PremiumThe Fly

MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy

2M ago

MeiraGTx price target lowered to $14 from $15 at BofA

PremiumThe Fly

MeiraGTx price target lowered to $14 from $15 at BofA

3M ago

MeiraGTx Announces Share Repurchase and Investor Lock-Up

PremiumCompany Announcements

MeiraGTx Announces Share Repurchase and Investor Lock-Up

4M ago

MeiraGTx initiated with a Buy at H.C. Wainwright

PremiumThe Fly

MeiraGTx initiated with a Buy at H.C. Wainwright

5M ago

MeiraGTx Reports Q3 2025 Results and Strategic Advances

PremiumCompany AnnouncementsMeiraGTx Reports Q3 2025 Results and Strategic Advances

5M ago

MeiraGTx reports Q3 EPS (62c) vs. (55c) last year

The Fly

MeiraGTx reports Q3 EPS (62c) vs. (55c) last year

5M ago

MeiraGTx sees cash runway into 2H27

The Fly

MeiraGTx sees cash runway into 2H27

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >